Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia

被引：0
|
作者：
Karagianis, J. [1 ]
Guilliver, A. [2 ]
Sun, B. [2 ]
Zhao, F. [2 ]
Watson, S. [2 ]
McDonnell, D. [2 ]
机构：
[1] Eli Lilly & Co, Toronto, ON, Canada
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2010年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：223 / 223
页数：1
相关论文
共 35 条
  • [1] Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia
    Hill, Angela L.
    Sun, Bin
    Karagianis, Jamie L.
    Watson, Susan B.
    McDonnell, David P.
    BMC PSYCHIATRY, 2011, 11
  • [2] Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia
    Angela L Hill
    Bin Sun
    Jamie L Karagianis
    Susan B Watson
    David P McDonnell
    BMC Psychiatry, 11
  • [3] Olanzapine Long-Acting Injection: A 24-Week, Randomized, Double-Blind Trial of Maintenance Treatment in Patients With Schizophrenia
    Kane, John M.
    Detke, Holland C.
    Naber, Dieter
    Sethuraman, Gopalan
    Lin, Daniel Y.
    Bergstrom, Richard F.
    McDonnell, David
    AMERICAN JOURNAL OF PSYCHIATRY, 2010, 167 (02): : 181 - 189
  • [4] Olanzapine long-acting injection for the maintenance treatment of schizophrenia: A 24-week, randomized, double-blind trial
    Detke, H. C.
    McDonnell, D. P.
    Kane, J. M.
    Naber, D.
    Sethuraman, G.
    Lin, D.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 151 - 152
  • [5] Efficacy and safety of olanzapine long-acting injection for maintenance treatment of schizophrenia
    Detke, H.
    McDonnell, D.
    Kane, J.
    Naber, D.
    Sethuraman, G.
    Lin, D.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S393 - S394
  • [6] Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
    Di Lorenzo, Rosaria
    Brogli, Alice
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 573 - 581
  • [7] Safety and efficacy of olanzapine long-acting injection for up to 6 years in patients with schizophrenia or schizoaffective disorder
    McDonnell, D. P.
    Detke, H. C.
    Choukour, M.
    Landry, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S319 - S320
  • [8] Risperidone Long-Acting Injection: Safety and Efficacy in Elderly Patients with Schizophrenia
    Catalan, Rosa
    Penades, Rafael
    JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE, 2011, 3 : 95 - 105
  • [9] OLANZAPINE LONG-ACTING INJECTION FOR SCHIZOPHRENIA: AN EVALUATION OF PATIENT FUNCTIONING DURING 24 WEEKS OF MAINTENANCE THERAPY
    Novick, D.
    Anand, H.
    Ascher-Svanum, H.
    Haro, J.
    Bertsch, J.
    Cui, Z.
    Detke, H.
    Mcdonnell, D.
    Montgomery, W.
    VALUE IN HEALTH, 2011, 14 (07) : A287 - A287
  • [10] Olanzapine long-acting injection in patients with schizophrenia at risk of relapse: 12-week switching data
    Detke, H.
    McDonnell, D.
    Andersen, S.
    Watson, S.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S435 - S435
1234